Sentences with phrase «derived tumor xenograft»
Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf G, English J, Kirschmeier PT, Velculescu VE, Paweletz CP, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R.: Establishment of patient - derived tumor xenograft models of epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics.
https://www.pennmedicine.org/
The researchers used an in vivo model of PARP inhibitor resistance in patient - derived tumor xenografts (PDXs).
NCI's efforts to develop new laboratory models of human cancer includes vastly increasing the number of human cancer cell lines (grown as two - dimensional and three - dimensional cultures) and patient - derived tumor xenografts.
These platforms include genetically engineered mouse (GEM) models, fallopian tube - derived cell lines, and patient - derived tumor xenografts.
Not exact matches
EZH2 inhibition delayed tumor onset in KDM6A - null cells and caused regression of KDM6A - null bladder tumors in both patient - derived and cell line xenograft models.
These days, mice grafted with human tumors, known as patient - derived xenograft (PDX) mice, are common in cancer research laboratories.
Over 300 patient - derived xenograft (PDX) tumors are available for engrafting into immunocompromised NSG ™ mice for shipment to your facility...
Finally, I have a category of «other cancers» with exomes published in 2011; these include pancreastic cysts and cell lines, gastric cancer tumors, and prostate cancer samples derived through mouse xenograft models.
On the contrary, recent evidence indicates that XMRV is a contaminant originating from the recombination of two mouse endogenous retroviruses during passaging of a prostate tumor xenograft (CWR22) in mice, generating laboratory - derived cell lines that are XMRV - infected.
A study by Pauli and colleagues in this issue of Cancer Discovery describes the creation of a precision cancer platform for patients with advanced disease, integrating DNA sequencing of patient tumors with the generation of patient - derived organoids and xenografts.
The approach is to use clinically relevant tumor models such as patient - derived xenografts (PDXs), as well as humanized and immunocompetent transgenic tumor - bearing mice to design rational combinations of novel and emerging cancer therapies, including tumor - targeting and immune - stimulating therapies, to ultimately improve treatment outcomes for cancer patients.
Over 170 carefully curated, well - characterized patient - derived xenograft tumor models are available for use in your facility, or use Horizon's comprehensive preclinical in vivo efficacy service.